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Upon binding their cognate receptors, ERα (ESR1) and ERβ (ESR2), estrogens activate
intracellular signaling cascades that have important consequences for cellular behavior.
Historically linked to carcinogenesis in reproductive organs, estrogens have also been impli-
cated in the pathogenesis of different cancer types of non-reproductive tissues including
the colon. ERβ is the predominant estrogen receptor expressed in both normal and malig-
nant colonic epithelium. However, during colon cancer progression, ERβ expression is lost,
suggesting that estrogen signaling may play a role in disease progression. Estrogens may
in fact exert an anti-tumor effect through selective activation of pro-apoptotic signaling
mediated by ERβ, inhibition of inflammatory signals and modulation of the tumor microen-
vironment. In this review, we analyze the estrogen pathway as a possible therapeutic
avenue in colorectal cancer, we report the most recent experimental evidence to explain
the cellular and molecular mechanisms of estrogen-mediated protection against colorec-
tal tumorigenesis, and we discuss future challenges and potential avenues for targeted
therapy.
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INTRODUCTION
Estrogens (including estrone, estriol, and the biologically active
metabolite 17β-estradiol) are cholesterol-derived steroid hor-
mones that are produced by aromatization of androgens primarily
in the ovary but also in other tissues (including muscle, adipose,
and nervous tissues). Estrogens play a central role in controlling
sexual behavior and reproductive functions, and are important
in the physiology of both men and women. Estrogens regulate
the development and homeostasis of a wide range of tissues and
organs, playing a crucial role in the cardiovascular, nervous, and
immune systems, as well as in bone metabolism (1). As a result,
estrogens have been implicated in numerous pathophysiological
conditions including cancer (2). Historically linked to carcinogen-
esis in reproductive tissues (ovary, uterus, and breast in women;
prostate in men), estrogens are also implicated in different cancer
types of non-reproductive tissues like the lung and the gastro-
intestinal system. The protective role of estrogens against carcino-
genesis specifically in the colon was the subject of a previous review
(3). Here, we aim to extend our analysis of estrogen signaling in
the colon, including the role of the tumor microenvironment and
immune evasion mechanisms; we also aim to discuss the poten-
tial role of manipulating the estrogen pathway as a therapy in
colorectal cancer (CRC).
ESTROGEN RECEPTORS: STRUCTURE, FUNCTION AND
MECHANISMS OF ACTION
Estrogens bind to two different estrogen receptors (ERs), ESR1
(ERalpha, or ERα) and ESR2 (ERbeta or ERβ), both members of
the nuclear receptor family (hereafter referred to as ERα and ERβ).
Like other members of this family, ERs are modular proteins orga-
nized in functional domains (N-terminal domain, DNA-binding
domain, hinge region, ligand-binding C-terminal domain) that
interact to mediate ligand-dependent gene expression (4, 5). ERα
and ERβ, which are encoded by two separate genes (ESR1 and
ESR2) located on different chromosomes, share a high degree of
sequence homology particularly in the DNA-binding region (97%
homology) and to a lesser extent in the ligand-binding region (59%
homology), which underlies their shared mechanism of action
with differences in their specificities and sensitivities for different
ligands. ERα and ERβ also have markedly different tissue- and
organ-specific expression patterns (5). In the classical mechanism
of action, estrogen-bound ERs located in the cytoplasm undergo
conformational changes that allow them to dissociate from scaf-
folding heat shock proteins (Hsp90 and Hsp70), to dimerize and
to translocate to the nucleus, where they can bind to specific DNA
sequences (ERE) in the promoter regions of target genes to mod-
ulate their expression (4, 6). In addition, ERs can also bind to
other transcription factors including Sp1, AP-1, and NFκB, allow-
ing them to extend their influence to genes that do not contain ERE
sequences in their promoter regions. Both ERα and ERβ inter-
act with receptor tyrosine kinases, scaffolding proteins, guanine
nucleotide exchange (G)-proteins, as well as other intracellular
signaling proteins, allowing them to activate a wide range of cyto-
plasmic signaling pathways, a process, which is independent of
transcription but that can ultimately impact on latent gene expres-
sion (5, 7, 8). The cumulative action of estrogens (as well as
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other steroid hormones) ultimately results from the integration
of signaling originating from receptors located in different cellu-
lar compartments (9). This provides a mechanistic explanation for
the delicate fine-tuning of responses to hormonal stimulation that
occurs in a tissue-specific fashion and depending on the cellular
milieu.
ERα and ERβ show differences in their biological functions
dependent on both nuclear and extra-nuclear signaling. Generally,
ERα promotes proliferative signaling through differential expres-
sion of pro- and anti-apoptotic proteins, as well as cyclin D1 to
promote cell cycle transition (10, 11). On the other hand, ERβ acts
as a dominant regulator, inducing a reduction in ERα-mediated
gene expression (when the two receptors are co-expressed) with
a consequent negative effect on cell proliferation (12). ERβ is
also able to exert standalone anti-proliferative effects (in the
absence of ERα) by activating pro-apoptotic signaling through
the p38/MAPK pathway (11, 13).
ESTROGEN RECEPTORS: ROLE IN NORMAL PHYSIOLOGY
AND CANCER
The individual contributions of ERα and ERβ in development and
physiology have been elucidated with the use of ERα−/−, ERβ−/−,
and double knockout mice (14). These mice survived to adulthood
with a variable degree of phenotypic abnormalities in different
tissues, including ovaries, uterus, mammary gland, prostate, testis,
bone, and brain. These phenotypic alterations are ER type-specific,
and they do not occur in the early phases of organ development.
Both ERs are necessary for the development and proper func-
tion of the ovaries. ERα is involved in the development of the
uterus and the mammary gland, as well as in bone physiology and
male fertility, whereas ERβ is important for neuronal development
(particularly in the somatosensory cortex) (4). Estrogens have a
physiological role in the regulation of ion channels in epithelia
of kidney, intestine, and lung to regulate whole body fluid and
electrolyte balance (15). Estrogen has a physiological role as a reg-
ulator of Cl− secretion in the colon, contributing to the salt and
water retention observed during the high estrogen states (16, 17).
Consistent with their role in normal physiology, estrogens and
ERs have been implicated in numerous human diseases includ-
ing osteoporosis, obesity, cardiovascular and neurodegenerative
diseases, and immune system disorders (2, 4, 18). Furthermore,
and not surprisingly given the spectrum of their downstream sig-
naling targets, estrogens contribute to cancer development and
progression in different tissue types, mainly in endocrine-related
reproductive tissues [mammary gland (19), ovary (20), uterus
(21), and prostate (22)] and also in non-endocrine-related tis-
sues [lung (23) and colon (24)]. The influence of ERα-mediated
proliferative signaling has been extensively studied in the context
of breast cancer, where pharmaceutical strategies to inhibit such
signaling have been a clinical success in the past 20 years (19, 25).
Inhibition of estrogenic signaling is achieved either through the
use of selective estrogen receptor modulators (SERM) like tamox-
ifen and raloxifene, or through inhibition of estrogen synthesis
via aromatase inhibitors. Proliferative signaling originating from
ERα is also involved in the pathophysiology of non-reproductive
tissues. For example, in the lung, ERα increases cellular pro-
liferation of normal lung fibroblasts and lung tumor cell lines
in vitro and tumor growth in immunocompromised mice (26),
and is a negative prognostic marker in non-small-cell lung cancer
independently of gender (27). While ERα promotes proliferation
of prostate cancer cells, estrogen action through ERβ is anti-
proliferative and anti-inflammatory in the prostate (28). ERβ has
anti-proliferative effects in breast cancer when co-expressed with
ERα, and studies show that loss of ERβ expression through pro-
moter hypermethylation occurs frequently in ductal breast cancer
(29). ERβ has also putative anti-proliferative effects in the ovary
and endometrium (30, 31). Beside this, the role of ERβ in non-
reproductive tissues has been studied particularly in the context
of gastrointestinal malignancies.
EVIDENCE FOR ESTROGEN RECEPTOR SIGNALING IN COLON
CANCER
ERβ is the predominant estrogen receptor expressed in both nor-
mal and malignant colonic epithelium, with limited or no expres-
sion of ERα observed in the colon (32). The expression of ERβ is
reduced during colonic tumorigenesis as compared to normal tis-
sue (12, 33, 34). ERβ is associated with stage and grade of disease,
and an inverse relationship between ERβ expression and tumor
progression has been reported in cell lines and clinical samples
(35–37). It is therefore hypothesized that estrogen-mediated sig-
naling exerts a protective role in CRC, further understanding of
this may benefit cancer prevention and also provide additional
therapeutic options for ERβ-positive tumors. The evidence for
this anti-tumorigenic effect comes from a plethora of different
studies, which are reviewed below.
EPIDEMIOLOGICAL EVIDENCE FOR THE ROLE OF STEROID HORMONES
IN CRC
The incidence of CRC is higher in men than it is in women (38).
With the exception of New Zealand and the USA (where rates are
decreasing for both sexes), incidence rates are increasing in men
while remaining steady among women (39, 40). Although not
originally designed to investigate CRC risk, the Women Health
Initiative study demonstrated that use of hormone replacement
therapy (HRT) in post-menopausal women was associated with
a 30% decreased incidence of CRC (41, 42). A number of other
observational studies have addressed this question [summarized
in Ref. (43)] and the majority report a decreased incidence of
CRC among HRT users (although some studies do not report
any difference), and a 30–60% decrease in CRC-related mortality.
Interestingly, a recent study of 503 post-menopausal women has
highlighted a role for ERβ in mediating the protective effects of
HRT. Decreased CRC risk was associated with duration of HRT use
specifically in ERβ-positive patients (OR for each 5 years interval:
0.87, 95% CI: 0.77–0.99) but not in ERβ-negative patients (OR:
1.02, 95% CI: 0.91–1.15) (44). This is an example of a relatively
novel area of epidemiologic research that has been termed molec-
ular pathological epidemiology (45). This type of study associates
an etiological factor (like an exposure factor) to specific molecular
changes in tumors, and analyzes interactive effects with the aim of
gaining insights into the carcinogenic process. A number of these
studies have analyzed in detail the exposure of post-menopausal
women to hormone therapy, and have shown that this is associ-
ated with reduced risk of specific sub-sets of CRC, according to
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the expression of cell cycle regulators, DNA methylation, somatic
mutations (BRAF and KRAS), and microsatellite instability (MSI)
(46–49).
Incidence of CRC varies greatly by geographical region, with
the highest rates seen in developed countries (Australia, New
Zealand, Western Europe, and North America) and lowest rates in
developing countries, particularly in Africa and Asia (38). These
differences reflect distribution patterns for known risk factors
for CRC (like smoking, obesity, and consumption of red meat),
including differences in diet, e.g., Asian countries extensively use
soy products containing phytoestrogens. In a recent meta-analysis
of retrospective studies, soy consumption was found to be associ-
ated with a 21% decreased risk of CRC in women but not in men
(50), a finding that might be related to the fact that soy supple-
mentation is more effective when combined with estrogens in vivo
(51). Furthermore, when people migrate from an Asian country
to the U.S., incidence of CRC in the migrants begins to rise to the
average of the U.S. (52).
Among the characteristics that are associated with the so-called
western lifestyle, obesity is an important established risk factor for
CRC in both men and women, although reported hazard ratios
vary greatly according to whether body mass index (BMI) or waist
circumference (WC) is used as a surrogate measure (53, 54). The
prevalence of adenoma and advanced polyps is higher in men than
women in all age groups except for people older than 70 years, and
a positive association between BMI and the prevalence of colonic
adenoma and advanced polyps was shown in young individu-
als of both gender and in premenopausal women according to
hormonal status (53). This further supports the role that steroid
hormones play in linking obesity to the increased risk of CRC,
which has been previously demonstrated in animal models (55).
Adipose tissue contributes to extra-gonadal testosterone aromati-
zation and estrogen production. Adipose tissue is also an estrogen
target tissue, and adipocytes express both ERα and ERβ, where they
are involved in estrogen-mediated control of adipogenesis, lipo-
genesis, lipolysis and adipocyte proliferation (18). Obesity results
in metabolic changes that can in turn promote colorectal car-
cinogenesis, and steroid hormones also modulate some of these
mechanisms. For example, hyperinsulinemia and insulin resis-
tance are associated with obesity, and insulin/insulin-like growth
factor (IGF-I) signaling promotes tumorigenesis (56). Mitogenic
leptin is also increased in obese patients (53, 57), and estrogens can
regulate leptin through ERα (58). A decrease in anti-inflammatory
adipokines is also linked to both obesity and risk of CRC, although
in a cohort study of post-menopausal women this did not reach
statistical significance in multivariate analysis (57). Obesity overall
is characterized by low-grade chronic inflammation and reduced
immunity, which also contribute to tumorigenesis (53). Further-
more, epidemiological studies have also linked physical activity
to the risk of different cancers including CRC, demonstrating
that increased exercise leads to reduced estrogen levels in post-
menopausal women and a modulation of menstrual function in
premenopausal women (59). Physical activity improves insulin
resistance, reduces hyperinsulinemia, and reduces risk for dia-
betes; it might also reduce systemic inflammation alone or in
combination with reduction in body weight through reducing
inflammatory cytokines in adipose tissue (59).
CLINICAL EVIDENCE FOR THE ROLE OF ERβ IN CRC PROGRESSION
The expression of ERβ declines during tumor progression (34, 60),
and analysis of clinical samples provided initial evidence that the
reduced expression of ERβ could relate to tumor stage and grade,
and to other characteristics of poor prognosis (including poorly
differentiated tissue, vascular invasion, and decreased apoptotic
index) (32, 33, 36). In a recent analysis of 1262 patients, expres-
sion of ERβ by immunohistochemistry correlated with progno-
sis in CRC: decreased expression was found in larger tumors
of higher grade, and expression levels were also inversely corre-
lated with Dukes stage. ERβ negativity was associated with a 54%
increased risk of CRC-specific death, and a poorer disease-free
survival (DFS) (35). Single-nucleotide polymorphisms (SNPs)
located in the 5′ regulatory region of the ERβ gene (but not of
ERα, progesterone receptor, or androgen receptor) were associ-
ated with improved survival after a diagnosis of CRC. These SNPs
could be markers of receptor isoforms expression or CpG island
methylation and transcriptional inactivation of ERβ (61). Further-
more, members of p160 ER co-activator superfamily AIB1 (SRC-
3/NCoA3) and TIF2 (SRC-2), which interact with ERβ to mediate
transcriptional activity, were up-regulated in adenomas and carci-
nomas compared to normal tissue; AIB1 was also associated with
increased overall survival in a cohort of 110 CRC patients (62).
PRE-CLINICAL EVIDENCE OF THE ROLE OF ERβ IN CRC
A number of in vitro studies supporting an inhibitory role for ERβ
in CRC progression have been previously described (3). Recently,
reported studies in mice have provided some in vivo evidence
for the role of ERβ in CRC. Analysis of colonic tissue in ERβ−/−
mice showed that loss of ERβ leads to hyper-proliferation, de-
differentiation, decreased apoptosis, and disruption of epithelial
tight junctions; surprisingly no tumor formation was reported
as hyper-proliferative cells moved faster to the surface of colonic
crypts and were subsequently shed in the lumen (63). Saleiro
and colleagues used the azoxymethane/dextran sodium sulfate-
induced mouse model of colitis-associated CRC to show increased
severity of clinical colitis in the absence of ERβ. This was coupled
to increased inflammation and higher grade of dysplasia specifi-
cally in the early phase of tumor development, suggesting that ERβ
might delay inflammation and neoplastic transformation (64).
Giroux et al. crossed ERβ−/− mice with ApcMin/+ C57BL/6J mice
to obtain ERβ−/−ApcMin/+mice, which showed increased number
and size of polyps, and tumors that were significantly larger than
those in control ApcMin/+ mice. (65). These data suggest that loss
of ERβ alone might not be sufficient to promote colorectal car-
cinogenesis, but that instead it would confer selective advantage
to transforming epithelial colonocytes by eliminating a protective
mechanism against genotoxic stress in the early phases of cellular
transformation, therefore accelerating tumorigenesis.
As there are numerous downstream signaling pathways mod-
ulated by ERβ, there are a number of potential mechanisms by
which ERβ exerts this protective effect. Gene expression profiles of
ERβ−/− ApcMin/+ mice suggested that modulation of the TGF-β
signaling pathway contributed to the protective role of estrogens
on intestinal tumorigenesis (65). Ectopic expression of ERβ in
SW480 CRC cells resulted in inhibition of proliferation and cell
cycle arrest in G1 phase, which was dependent on decreased c-Myc
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and altered expression of different cell cycle proteins. Furthermore,
when ERβ-transfected SW480 cells were implanted in the fat pad of
SCID/Beige mice in the presence of estrogen, ERβ over-expression
resulted in a 65% reduction in tumor weight (37). Similarly, when
ERβ-overexpressing HCT-116 cells were xenografted into BALB/c-
nu nude mice, there was an 18% reduction in tumor growth, with
a greater tumor reduction (89%) seen in combination with ralox-
ifene (66). ApcMin/+ mice treated with a SERM (raloxifene) or
an anti-estrogenic compound (Gonadorelin) showed a 65–75%
inhibition in intestinal tumor multiplicity and size, and a 94–98%
inhibition of polyps >2 mm in size, with decreased expression
of β-catenin, cyclin D1, laminin 1b, and stem-like cells mark-
ers (67). Using the azoxymethane/dextran sodium sulfate model,
Armstrong and colleagues showed that estrogen treatment reduced
expression of ERβ while increasing ERα (68), and a similar find-
ing was previously reported in rats treated with soy isoflavonoids
(69), suggesting that the ratio of ERβ/ERα might have clinical
implications in protecting against CRC (70). However, differen-
tial expression of ERβ isoforms in different tissues and organs, or
during tumor progression, may also contribute to the outcome of
estrogen signaling.
ERβ ISOFORMS AND THEIR ROLE IN COLORECTAL CANCER
Four alternative isoforms of ERβ have been described so far
(ERβ2/ERβcx, ERβ3, ERβ4, ERβ5), arising from alternative splic-
ing of the last coding exon of the receptor; these proteins have a
truncated or otherwise altered C-terminal domain (12). These iso-
forms were initially cloned from a human testis cDNA library and
shown to have different pattern of tissue distribution (71). The C-
terminal region of the ER contains the ligand-binding domain and
is also involved in transcriptional activation, receptor dimeriza-
tion, nuclear translocation and interaction with transcription co-
regulators (4). Therefore, modifications in this particular region
can have a profound impact on the activity and biological func-
tion of ERβ. A recent study addressed the functional role of ERβ
isoforms, showing that ERβ2–4–5 are lacking intrinsic ligand-
dependent transactivation activity, making ERβ1 (wild-type) the
only functional receptor isoform. However, ERβ2–4–5 form het-
erodimers with ERβ1, and they can enhance transcriptional activ-
ity induced by ERβ1 at physiological concentrations of estrogen
(72). ERβ isoforms were identified in two CRC cell lines (HCT8
and HCT-116) by RT-PCR, with two more cell lines (DLD-1 and
LoVo) reported negative for all isoforms (73). ERβ2 and ERβ5
were the predominant isoforms identified in 91 primary colorec-
tal carcinoma samples by immunohistochemistry, using custom-
made antibodies raised against isoform-specific peptides in the
C-terminal region (74). ERβ2 was decreased in tumor tissue com-
pared to normal adjacent tissue, and associated with right-sided
tumors and the presence of lymph node metastases, while ERβ5
was expressed in all tumor samples and also in a panel of 20 CRC
cell lines (74). The specific role of ERβ isoforms in CRC is yet to be
fully elucidated; however, it is plausible that the co-expression of
different isoforms of the receptor (namely ERβ2 and ERβ5), even
in the presence of low levels of full-length ERβ, would complicate
the estrogen-mediated signaling involved in tumor suppression,
and therefore, this needs to be taken into account when designing
therapeutic strategies targeting the estrogen pathway.
ESTROGEN RECEPTORS, TUMOR LOCATION, AND
MICROSATELLITE INSTABILITY
Colorectal cancers can arise from different regions of the colon,
and their location impacts on their biological characteristics.
Specifically, the right (proximal) colon and the left (distal) colon
have different embryological origins (the midgut and the hindgut,
respectively), which are reflected in differences in histopathology,
molecular biological patterns, metastatic spread, and mutational
profile of tumors (75–77). Proximal and distal tumors also have
differences in their respective microbial flora, which can impact
on tumor progression (78). Proximal tumors have a higher fre-
quency of MSI (79), a pathway associated with loss of mismatch
repair proteins resulting in accumulation of errors in DNA repli-
cation. Estrogens appear to be somehow linked to the left-right
dichotomy in CRC: women develop more proximal, and men more
distal colon and rectal cancers, and female sex is an independent
predictor of proximal cancers (80). Furthermore, the incidence
of proximal cancers in women increases with age, while the same
is not observed in men (80). The reduction of ERβ expression
is more prominent in proximal CRC (21%) than in distal cases
(7%) (36), providing a putative rationale for the aforementioned
gender disparities. MSI occurs more frequently on the right side
of the colon, and in female patients (81), and a recent analysis
reports an association of MSI with proximal cancers, hyperme-
thylation (CIMP phenotype), and inflammatory subtype of CRC
(79). Endocrine factors are associated with MSI tumors (82), with
a significant interaction among age, sex, and MSI: women are more
likely than men to have MSI tumors at an older age (82). This can
be explained, at least in part, by the ability of estrogen to induce
the expression of mismatch repair proteins (MLH1 and MSH2)
via ERβ (83).
Epidemiological differences have also been reported accord-
ing to tumor location. Early ulcerative dysplastic lesions in the
left colon are more likely to progress than those originating in
the right colon (84). However, mortality rates are higher in right
colon than in left-colon cancers (75, 79). Molecular pathologi-
cal epidemiology studies have also provided some evidence that
post-menopausal hormone therapy use could be associated with
reduced risk of CRC selectively for distal tumors that are KRAS
wild-type and MSI-low (48, 49).
The division between left and right colon might not be as
dichotomous as previously thought, and instead represent a more
homogenous continuum along the colon length (85). This is sup-
ported by linear changes in the distribution pattern of different
molecular markers along the intestine (86, 87), and also by changes
in recurrence rates according to tumor location (88). Furthermore,
a recent study showed that within the right colon, there are dif-
ferences between more distal and more proximal regions, where
higher percentages of stage IV, node-positive or metastatic can-
cers, and higher mortality rates are reported in the more proximal
portion (transverse colon) of the right colon (89).
Although more studies are needed to address the role of estro-
gens and differences in ERβ expression in different colon locations,
the data reviewed here suggest that estrogen signaling might be (at
least in part) responsible for the gender gap in proximal versus
distal colon tumors and associated differences in biology and
mortality rates.
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ESTROGEN-MEDIATED REGULATION OF TUMOR
MICROENVIRONMENT AND IMMUNE SURVEILLANCE
Estrogen and other ER ligands modulate both innate and adaptive
immunity, which is reflected in gender differences during autoim-
munity (90). The contribution of inflammatory networks and
immune-escape mechanisms in the tumor microenvironment in
colorectal carcinogenesis is well established (91, 92). Yet, how ER-
dependent pathways contribute to the regulation of the inflamma-
tion within the tumor microenvironment is not well understood.
Analysis of genome-wide gene expression changes in three CRC
cell lines transfected with ERβ showed that IL-6 signaling pathway
represented a significantly enriched sub-network, and RT-PCR
confirmed the down-regulation of IL-6 (as well as 10 different
IL-6 target genes) by ERβ in SW480 cells (93). This has impor-
tant potential consequences in modulating a tumor-promoting
microenvironment, as IL-6 activate the STAT3 transcription fac-
tor in epithelial, myeloid cells, and myofibroblasts, promoting
CRC tumorigenesis (94, 95). Different ER ligands regulate the
homeostasis of bone marrow myeloid and lymphoid progenitors
of dendritic cells (DC), and also modulate DC activation and
production of inflammatory mediators (96). Estrogen signaling
promotes the granulocyte macrophage-colony-stimulating factor
(GM-CSF)-mediated differentiation of myeloid progenitor cells
into CD11b+ DC, through ERα-mediated activation of interferon
regulatory factor 4 (IRF4) (97). Estrogen affects DC to regulate
response to TLR agonists (98). Therefore another plausible mech-
anism by which estrogen could exert anti-tumorigenic effects in
CRC would be through the regulation of DC-mediated immune
surveillance, although this hypothesis needs to be addressed exper-
imentally. Furthermore, the estrogen signaling in immune cells is
complicated by multiple effects on different cell types, as estrogen
is also known to have anti-inflammatory effects on monocytes
and macrophages, and to enhance CD4+ T cell response (96).
ERβ is also involved in mediating anti-inflammatory responses.
Using human osteosarcoma, U2OS cells expressing ERβ as a
model, Cvoro and colleagues showed that both estradiol and ERβ-
selective agonists reduced the activation of 18 pro-inflammatory
genes (including TNF-α, IL-6, and CSF2) induced by TNF-α (99).
This suggests that selective activation of ERβ-mediated signal-
ing might have a negative impact on tumorigenesis also through
down-regulation of pro-tumorigenic inflammatory signaling in
the tumor microenvironment. Moreover, cytokines produced by
the tumor microenvironment could feedback on estrogen sig-
naling through increased 3β-hydroxysteroid dehydrogenase gene
expression, therefore inducing the biosynthesis of active steroid
hormones from the inactive adrenal steroid dehydroepiandros-
terone in peripheral target tissue (100). Finally, work with the
ERβ−/− mouse model showed that a diet rich in estrogenic
isoflavones and fiber could modify the composition of intesti-
nal microbiota through ERβ in female mice, a finding, which
have important consequences since the microbiota is known to
influence local inflammation and intestinal tumorigenesis (101).
ER SELECTIVE LIGANDS AND POTENTIAL AVENUES FOR
TARGETED THERAPY
Plant-derived flavonoids bind to both ERα and ERβ and
are considered protective agents against endocrine-dependent
tumors, among other potentially beneficial effects on human
health. This provides a mechanistic explanation for some epi-
demiological evidence linking diet to CRC risk. In the spe-
cific context of colorectal carcinogenesis, naringenin (5,7,4′-
trihydroxyflavone) and quercetin (2-3,4-dihydroxyphenyl-3,5,7-
trihydroxy-4H-1-benzopyran-4-one) induced apoptosis in CRC
cells (102, 103). Both compounds activate the p38/MAPK signal-
ing leading to activation of pro-apoptotic caspase 3 in DLD-1
colon cancer cells expressing ERβ. Quercetin also increased the
expression of the oncosuppressive protein PTEN and decreased
cyclin D1 promoter activity (103). However, the potential med-
ical use of flavonoids in cancer has not been addressed beyond
pre-clinical studies.
Other chemical compounds used in industry and agriculture
(termed xenoestrogens, or endocrine-disrupting chemicals) nega-
tively impact on human health and have colorectal-specific effects.
For example, bisphenol A (BPA) bind to both ERα and ERβ
and act as an estrogen antagonist by inhibiting estrogen-induced
pro-apoptotic signaling and gene expression (104). An increased
research-driven awareness of the harmful effects of endocrine
disruptors in recent years have resulted in policy changes con-
cerning the use of these compounds in human activities, although
the broad impact of this policy implementation on human dis-
ease is yet to be fully elucidated, and more basic research is
needed to address mechanisms of action and physiological roles
of xenoestrogens (105).
The development of ER subtype-selective ligands has been a
very active field of research over the past 10 years. Consequently,
a large number of ERβ-specific agonists have been designed,
although very few show potential as anti-cancer drug candidates
(106). Isoquinolinone derivatives have been tested on different
cancer cell lines and inhibit C-26 CRC cell proliferation. SR16388,
another compound with ERβ-specific activity, has shown promis-
ing properties for the treatment of non-small cell lung cancer,
CRC, and androgen-independent prostate cancer (106).
CONCLUSION
Estrogen signaling has an anti-tumorigenic role in the colonic
mucosa, through selective activation of pro-apoptotic signaling
mediated by ERβ, inhibition of inflammatory signals, and mod-
ulation of the tumor microenvironment and different immune
surveillance mechanisms (Figure 1). Selective loss of ERβ expres-
sion during CRC progression highlights the importance of this
oncosuppressive signaling, and provides difficulties in using this
same signaling as a therapeutic target.
Two main challenges characterize the future of this research
field. First, it is of crucial importance to further characterize ERβ
expression in patients, identifying a specific subset of patients with
decreased ERβ loss or differential expression of ERβ isoforms, in
order to help stratification and patient selection for future ther-
apies targeting estrogen signaling. Some of these questions are
currently being investigated (107). Different therapeutic strategies
are being studied to selectively target ERβ-dependent signaling,
requiring the concomitant development of an appropriate diag-
nostic companion tool. Second, the down-regulation of ERβ and
the subsequent loss of protective signaling in advanced tumors
warrant increased research into the mechanisms involved, to
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FIGURE 1 |Tumor-suppressive functions of ERβ in CRC. The potential
impact of estrogen signaling through ERβ in colorectal carcinogenesis
could be exerted via activation of pro-apoptotic signaling, regulation of
mismatch repair proteins, modulation of the inflammatory tumor
microenvironment, activation of immune surveillance mechanisms,
or down-regulation of immune evasion mechanisms. Selective loss
of ERβ in different location within the large intestine promotes
tumorigenesis.
address the potential for therapeutic re-activation of oncosuppres-
sive signaling. A positive feedback mechanism has been described
in vitro where estrogen stimulation leads to increased ERβ protein
expression, reinforcing pro-apoptotic signaling in colon cancer
cells (108). This mechanism is lost during colon cancer progres-
sion due to unknown factors. Studies in breast cancer, where
ERβ-selective loss is also reported, suggest that epigenetic mech-
anisms (namely, promoter methylation and histone acetylation)
might be involved. Treatment of breast cancer cells with a combi-
nation of de-methylating agents and histone deacetylase (HDAC)
inhibitors fully restored ERβ expression (109), and recently a ther-
apeutic approach with combinations of HDAC inhibitors and
SERMs (hybrid drugs termed SERMostats) is being investigated in
breast cancer (110). In CRC, the adenovirus-mediated induced re-
expression of ERβ showed promising results in pre-clinical studies
(111). The design of novel and specific SERMs with selective differ-
ential anti-estrogen and estrogen-like activities in different target
tissues will greatly advance clinical development of therapeutic
strategies for the estrogen pathway. It will be crucial to overcome
toxicity issues related to current SERMs and to develop strategies
allowing to conserve beneficial estrogen effects in certain tissues
while simultaneously targeting signaling involved in cancer initi-
ation and progression. One such strategy has recently emerged,
combining SERMs and estrogens in what has been named tissue
selective estrogen complex (TSEC), to elicit a blend of ER agonistic
activities (112).
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